| |
Wednesday, November 20, 2024 | 11am ET / 8am PT Join us for a deep dive into electronic Clinical Outcome Assessment (eCOA) systems. We'll explore the latest trends and strategies tailored for increasingly complex clinical trial environments. Learn about the current and future state of eCOA technology, potential areas for enhancement, ways to leverage effectively, and more. Register now. 
|
|
Today’s Big NewsNov 13, 2024 |
|
De-risk clinical trials with Foresight CLARITY’s ultra-sensitive MRD detection. Foresight CLARITY is IUO-ready for prospective trials through our CLIA-registered central lab.
Learn more about Foresight CLARITY™️ 
|
|
| By Gabrielle Masson Adaptimmune Therapeutics is prepping for another FDA submission after 42% of patients with sarcoma responded to the company's investigational cell therapy in a pivotal phase 2 trial. |
|
|
|
By Fraiser Kansteiner As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in acquiring external products with the potential to launch in the near term, according to a new loss of exclusivity report from Leerink Partners. |
By Angus Liu The current FDA commissioner said that Trump’s first FDA head, Scott Gottlieb, was the perfect choice at the time. |
By Nick Paul Taylor A hidden tab in an Excel spreadsheet published nine months ago has wiped $12 billion off Amgen’s market cap. The tab contains data on bone density changes in patients who received Amgen’s obesity prospect MariTide in a phase 1 trial. |
|
Wednesday, November 20, 2024 | 11am ET / 8am PT Join us to discover how to overcome challenges, and learn about practical solutions for scalability and safety in cell therapy manufacturing. Don't miss out, register today. 
|
|
By Conor Hale The company describes the precision medicine test as the first of its kind to offer simultaneous whole exome sequencing and whole transcriptome sequencing. |
By Nick Paul Taylor BioNTech is upping its bet on a PD-L1xVEGF-A bispecific, paying $800 million upfront to buy its Chinese partner Biotheus and secure full rights to a leading prospect in the white-hot immuno-oncology space. |
By Zoey Becker As Xarelto generics continue to eat away at sales, Bayer's Nubeqa and Kerendia are picking up the slack while Regeneron-partnered Eylea makes for a solid base. |
By Nick Paul Taylor Zimmer Biomet has hired The Terminator to tell the world that “if you rest, you rust.” The manufacturer of orthopedic medtech products is getting its message about how to increase mobility and maintain joint health out via its newly appointed chief movement officer: Arnold Schwarzenegger. |
By Zoey Becker The company last month opted to end development of its flagship seizure drug while exploring "strategic alternatives" to maximize shareholder value ahead of a planned FDA meeting. |
By Nick Paul Taylor Syros Pharmaceuticals’ blood cancer prospect tamibarotene has failed another study, triggering a default on a loan and wiping 85% off the share price of the beleaguered biotech. |
By Conor Hale GE HealthCare tapped imaging provider RadNet for an artificial intelligence collaboration aimed at reshaping the radiology diagnostic workflow. |
Fierce podcasts Don’t miss an episode |
| This week on "The Top Line," we take a closer look at this year’s biotech graveyard, which tracks biotechs that have closed or are winding down. |
|
|---|
|
|
|
Gene therapy holds the extraordinary potential to transform global health care, boasting a pipeline that has grown tremendously through the years. Download the QPS white paper for insights into the regulatory landscape for future cell and gene therapies. 
|
|
Whitepaper The use of prefilled syringes to administer biotherapeutics is beginning to gain traction because they offer a range of stability, efficacy, and patient safety benefits. Download this white paper to learn how Lonza has developed a novel workflow to ensure confidence regarding functionality in PFS and autoinjectors. Presented by Lonza |
Whitepaper Explore the robust cross-platform agreement between scRNA-seq and bulk RNA-seq, ensuring consistent and reproducible data on immune cell presence. Sponsored by: IQVIA Laboratories |
Whitepaper This e-book explores 7 factors that are critical to the success of emerging biopharma companies, whether they plan to out-license, partner, or launch & commercialize products. It’s an essential resource for emerging companies with products in all stages of development. Sponsored by: Blue Matter |
Whitepaper Unlock the secrets to faster, cost-effective biologics production with intensified biomanufacturing – download the whitepaper and power up your bioprocessing game! Sponsored by: Syngene International Ltd. |
Whitepaper Discover how independent adjudication can safeguard your clinical trials from misidentified adverse events and enhance the credibility of your results. Sponsored by: WCG |
Whitepaper Learn how to evaluate quality documentation to help you select the right raw materials at early decision points for your cell-based manufacturing processes. Presented by: Thermo Fisher Scientific |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| The Lighthouse at Pier 61 in New York City |
|
|
| |
|
